Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18784278 | 1.00 | PKM (0.46) | PKMALDH1A1POLBLMNAKMT2A | |
| SCHEMBL18784364 | 0.96 | PKM (0.46) | PKMALDH1A1POLBLMNAKMT2A | |
| SCHEMBL18784365 | 0.96 | PKM (0.46) | PKMALDH1A1POLBLMNAKMT2A | |
| SCHEMBL18784286 | 0.80 | KMT2A (0.39) | PKMALDH1A1POLBLMNAKMT2A | |
| SCHEMBL18784283 | 0.80 | KMT2A (0.39) | PKMALDH1A1POLBLMNAKMT2A | |
| SCHEMBL21219270 | 0.74 | MEN1 (0.42) | PKMKMT2AMEN1GAA | |
| SCHEMBL21219288 | 0.74 | TBXA2R (0.40) | ALDH1A1LMNAKMT2AMEN1 | |
| SCHEMBL18784328 | 0.73 | ALDH1A1 (0.42) | ALDH1A1 | |
| SCHEMBL18784331 | 0.73 | ALDH1A1 (0.42) | ALDH1A1 | |
| SCHEMBL862348 | 0.72 | PKM (0.58) | PKMALDH1A1POLBLMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3162794-B1 | ALKYL SUBSTITUTED AZETIDINES AS CATIONIC LIPID | KYOWA KIRIN CO LTD (JP) | 2020-09-16 | — | — | EP | disclosed |
| US-20170224619-A1 | CATIONIC LIPID | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2017-08-10 | — | — | US | disclosed |
| EP-3162794-A1 | CATIONIC LIPID | Kyowa Hakko Kirin Co., Ltd. (JP) | 2017-05-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170224619-A1 | CATIONIC LIPID | NPC1L1, NPC1, SGMS1 | PKM 4115/4885ALDH1A1 3134/4885POLB 819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.